Where Mounjaro comes from — the medicine, its maker and the supply chain that matters

The misconception: Mounjaro is just repackaged semaglutide

A surprisingly common belief, particularly online, is that Mounjaro and Wegovy are essentially the same medicine under different branding. They are not. Mounjaro's active ingredient is tirzepatide, a molecule Eli Lilly developed over roughly a decade of research into gut-hormone biology. Semaglutide (found in Wegovy) works on a single receptor pathway. Tirzepatide targets two: the GIP receptor and the GLP-1 receptor simultaneously. That dual action is what makes it structurally and pharmacologically distinct, not a marketing choice. The NHS medicines page for tirzepatide describes this dual mechanism clearly if you want a patient-level explanation written by UK clinicians.

The confusion probably persists because both medicines are weekly injections used for weight management, and both cause similar early side effects. But the molecule itself, the company behind it, and the development pathway are all different. Getting this straight matters partly for informed consent (you should know what you are taking) and partly because counterfeiters exploit brand confusion. A pen labelled as one GLP-1 medicine has sometimes been found to contain a completely different substance.

One practical check worth doing before you trust any online seller: look up the pharmacy on the GPhC's public register by name or registration number. It takes under a minute and immediately tells you whether the pharmacy is licensed to dispense prescription medicines in the UK. If it is not on the register, walk away.

Where Mounjaro is made and how it reaches a UK pharmacy

Eli Lilly manufactures tirzepatide at facilities across its global network, with production scaled significantly since Mounjaro received its first major approvals in 2022 and 2023. The finished product (the pre-filled KwikPen) enters the UK through the MHRA-regulated supply chain, meaning importers, wholesalers and dispensing pharmacies must all hold the appropriate licences. This is not administrative paperwork for its own sake: it is the mechanism that ensures the pen you inject contains what the label says, at the stated concentration, stored at the required temperature throughout transit.

If you want to read further about tirzepatide's origins as a compound, including its development rationale, the tirzepatide origins page goes into the science in more detail. The short version: Lilly's researchers were exploring molecules that could mimic the natural GIP and GLP-1 hormones released after eating. Tirzepatide is a synthetic peptide designed to bind both receptors with high affinity. It took years of refinement before it was suitable for clinical trials.

Supply shortages affected the UK market through 2023 and into 2024 as global demand outpaced manufacturing capacity. Lilly has since expanded production. At any given time, though, specific pen strengths may be in shorter supply than others, which is one reason clinical oversight across each repeat order matters rather than simply auto-renewing a subscription.

What the licensed UK supply chain actually protects you from

The MHRA has documented counterfeit Mounjaro pens circulating in the UK, including the discovery of an illicit manufacturing site in Northampton in October 2025 producing fake tirzepatide pens. Across 2025 alone, enforcement actions recovered roughly 20 million doses of illegally traded weight-loss medicines, with an estimated street value around £45 million. Some counterfeit pens seized earlier in the enforcement programme were found to contain insulin, a substance that, injected by someone without diabetes in a weight-loss dose, can cause dangerously low blood sugar.

The licensed supply chain exists to prevent exactly this. Pharmacies registered with the GPhC, dispensing under MHRA oversight, sourcing from authorised distributors, each step is a check that the pen is what it claims to be. You can read more about the counterfeit risks and how to spot red-flag sellers on our Mounjaro overview page.

Sellers who offer Mounjaro without requiring a prescription are a red flag in themselves. Beyond the question of whether the medicine is genuine, a prescriber's assessment is not bureaucracy: it checks for contraindications, considers your other medicines, and sets a starting dose appropriate for your health. The MHRA's Yellow Card scheme is where you can report both suspected side effects and suspect sellers, both are worth flagging.

How this shapes what to look for when accessing treatment

Understanding where Mounjaro comes from makes the access question clearer. There is one manufacturer. There is one licensed product, the KwikPen, in six UK strengths from 2.5mg up to 15mg. And there is one legal route to it: a prescription issued following a clinical assessment. Anything that departs from that picture warrants caution.

For patients considering private treatment, the clinically appropriate route is a regulated UK online pharmacy or clinic, with a GPhC-registered prescriber reviewing your consultation before a prescription is issued. At nume, that review is done by a real prescriber (a named, GPhC-registered Independent Prescriber who reads your answers the same day) not an automated process. Our about page describes how our pharmacy and clinical team are structured.

Injecting safely is also part of knowing your medicine. Knowing where to give Mounjaro shots, including the recommended sites such as the abdomen, thigh, and upper arm, and why rotating between them matters, is something every new user should get comfortable with before their first dose. If you are new to self-injection, our guide to injection sites covers the practical detail. For questions about the pen itself, including what comes in the box, the pen and needle information page answers the most common queries.

Thinking about the cost of private treatment is reasonable, and the Mounjaro cost page gives factual context on UK pricing without any pressure. If you are ready to explore whether tirzepatide is suitable for you, the right next step is a conversation with a prescriber. Speak to our prescribers through a free consultation, there is no obligation, and it starts with your health history, not your payment details.